Boston Biomedical Leadership and Directors

Boston Biomedical is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., which is traded on the Tokyo Stock Exchange. Its Board of Directors can be found at here.

Boston Biomedical’s Board of Directors includes executive leadership of Sumitomo Dainippon Pharma Co., Ltd., and an external board member, William J. Rutter, PhD.

Executive Leadership

Patricia S. Andrews Industry veteran and former Chief Operating Officer Patricia S. Andrews was appointed to the role of Chief Executive Officer of Boston Biomedical in April 2017. Since joining the Company in 2013, Ms. Andrews has been a key driving force leading all aspects of commercial operations and medical affairs. Ms. Andrews’ extensive experience and proven track record of operational success will be instrumental in driving the Company forward into the next stage of growth and innovation through expanding our robust clinical pipeline, initiating additional clinical studies for our first-in-class compounds across multiple tumor types, and setting the foundation for future commercialization of late-stage compounds.

Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte, a U.S.-based biopharmaceutical company, where she led the transition from a clinical-stage research and development organization to a successful commercial enterprise, with the launch of its first-in-class, first-in-disease orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.

Prior to Incyte, Ms. Andrews spent 17 years at Pfizer, culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
Kazuo Koshiya, PhD In April 2017, Dr. Koshiya was appointed to the Global Head of Oncology for Sumitomo Dainippon Pharma Group, taking the lead in the Company’s overall oncology business, one of its core therapeutics areas. Under Dr. Koshiya’s leadership, Sumitomo Dainippon Pharma (DSP Cancer Institute, Oncology Clinical Development Unit), Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. (Headquarters: Lehi, UT, U.S., CEO: David J. Bearss) will collaborate on research and development with the goal of continuously creating innovative compounds and accelerating filings and approvals of compounds in the development pipeline in order for oncology products to contribute to company performance as early as possible. In January 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s oncology and hematology portfolios.

Since joining Sumitomo Dainippon Pharma in 2011, Dr. Koshiya has led the establishment of the global R&D and business organizations for oncology. Dr. Koshiya will oversee the Company’s overall oncology business, one of its core therapeutics areas.

Prior to Sumitomo Dainippon Pharma, Dr. Koshiya worked for Astellas Pharma for more than 20 years in Japan, the US, and the Netherlands. His responsibilities at Astellas included drug discovery, clinical development, R&D management, and business strategy. From 2007 to 2011, Dr. Koshiya served as Vice President, Product and Portfolio Strategy at Astellas headquarters. One of his achievements during this period was to develop and implement Astellas’ market entry strategy for oncology. Before joining industry, Dr. Koshiya was Assistant Professor of Neurophysiology at Kanazawa University. Dr. Koshiya earned his PhD in neuropharmacology from Tokyo Institute of Technology and a degree in pharmaceutical medicine from the European Center of Pharmaceutical Medicine in Switzerland.

Board of Directors

Dr. Rutter is Chairman and Founder of Synergenics, LLC, which owns and controls a portfolio of biotechnology companies at various stages of development.

In his academic career, Dr. Rutter joined the University of California–San Francisco (UCSF) as head of the newly formed department of Biochemistry and Biophysics in 1968, and played a key role in developing UCSF into a major scientific institution. In research, he is particularly known for the discovery of the enzymes involved in the expression of DNA (RNA polymerases), the first cloning of the insulin gene, the cloning of hepatitis B virus (HBV), and formation of an HBV-like particle that provided the basis for a safe and protective vaccine.

With 2 colleagues, Dr. Rutter founded Chiron in 1981, a pioneering biotech firm that developed the first recombinant vaccine (against HBV) with Merck and a process for manufacturing insulin from yeast with Novo-Nordisk. Chiron was the first to clone the AIDS (HIV) virus and to discover, clone, and sequence the hepatitis C virus (HCV). Chiron developed quantitative diagnostic tests for HIV, HBV, and HCV, thus providing the means for eliminating blood contaminated with these viruses, a major contribution to public health worldwide. Chiron developed and promulgated the concept of “viral load” as the basis for determining disease status, as well as the basis for developing and evaluating antivirals and other treatment protocols for these and other diseases.

Prior to Chiron, Dr. Rutter was a consultant to Abbott Laboratories for about 20 years, and a member of the Amgen Scientific Advisory Board. Dr. Rutter’s past board memberships include Novartis, Sangamo Biosciences, Cytokinetics, Nugen, Oscient Pharmaceuticals, and Epitomics.

Dr. Rutter also currently serves on the boards of Eureka Genomics, Apexigen, One Globe, and Cellworks. He is Chairman of the Synergenics companies: Synco Biopartners, ReLIA Diagnostic Systems, Numera Health, Ventria Bioscience, Humabs Biomed, Pathologica, and BioEnergenix.

Dr. Rutter is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has received numerous awards for his contributions to science and the biotechnology industry.

Join Our Team

We are looking for motivated, passionate and skilled scientists and commercial team members.

Learn More